Skip to main content

Table 18 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the VAS, for the subgroup in Ireland

From: Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

  EQ-5D-3L at 6 months (mean) EQ-5D-3L at 12 months (mean) Difference between 12 and 6 months EQ-5D-3L (95% CI) Effect size (Cohen’s D)a n % reporting 3L score increase
3L-VAS
 Improved 0.73 0.84 0.10 (− 0.02 to 0.24) 0.41 23 39
 No change 0.92 0.71 − 0.20 (− 0.48 to 0.06) − 0.67 12 25
 Worsened 0.82 0.82 0.00 (− 0.08 to 0.09) 0.00 13 23
  EQ-5D-5L at 6 months (mean) EQ-5D-5L at 12 months (mean) Difference between 12 and 6 months EQ-5D-5L (95% CI) Effect size (Cohen’s D) n % reporting 5L score increase
5L-VAS
 Improved 0.76 0.83 0.06 (0.00 to 0.14) 0.30 23 48
 No change 0.91 0.72 − 0.19 (− 0.47 to 0.09) − 0.61 12 33
 Worsened 0.84 0.81 − 0.02 (− 0.07 to 0.01) − 0.18 13 23
  1. aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large